During the past decade, Hospital Lluís Alcanyís conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 5 clinical trials were completed, i.e. on average, 29.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Lluís Alcanyís" #1 sponsor was "Spanish Lung Cancer Group" with 4 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Centro Nacional de Investigaciones Oncologicas CARLOS III" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Francisco Colomina Climent" with 1 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Lluís Alcanyís" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Lluís Alcanyís" are "Non Small Cell Lung Cancer" (3 trials), "Atrial Fibrillation" (2 trials), "Rhinoconjunctivitis" (2 trials), "Acute Respiratory Failure" (1 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Hospital Lluís Alcanyís" in a lesser frequency.

Most popular intervention types in "Hospital Lluís Alcanyís" are "Drug" (14 trials), "Biological" (3 trials), "Procedure" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (1 trials), "Allergovac Poliplus" (1 trials), "Anastrozole" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials) and "Beta blocker" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Lluís Alcanyís" are 21 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Lluís Alcanyís". 1 are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Hospital Lluís Alcanyís, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Lluís Alcanyís, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".